Processa Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| PROCESSA PHARMACEUTICALS, INC. | |
| By: | /s/ George Ng |
| George Ng | |
| Chief Executive Officer (Principal Executive Officer) | |
| Dated: | March 29, 2024 |
| By: | /s/ James Stanker |
| James Stanker | |
| Chief Financial Officer (Principal Financial and Accounting Officer) | |
| Dated: | March 29, 2024 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the dates indicated.
| Name | Capacity | Date |
|---|---|---|
| /s/ George Ng | Chief Executive Officer | March 29, 2024 |
| George Ng | ||
| /s/ James Stanker | Chief Financial Officer | March 29, 2024 |
| James Stanker | ||
| /s/ David Young | President of Research and Development and Director | March 29, 2024 |
| David Young | ||
| /s/ Khoso Baluch | Director | March 29, 2024 |
| Khoso Baluch | ||
| /s/ James Neal | Director | March 29, 2024 |
| James Neal | ||
| /s/ Geraldine Pannu | Director | March 29, 2024 |
| Geraldine Pannu | ||
| /s/ Justin Yorke | Director | March 29, 2024 |
| Justin Yorke | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.